Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, With Executive Guides and Customization 2023 to 2027

1.1 Antimicrobial Resistance - Strategic Situation Analysis
1.2 Guide for Executives and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors

2.1 The Threat and Opportunity of Antimicrobial Resistance
2.2 Defining the Opportunity
2.2.1 Revenue Market Size
2.3 Methods and Sources
2.3.1 Methodology
2.3.2 Sources
2.3.3 Authors
2.4 Perspective: Healthcare and the IVD Industry
2.4.1 Global Healthcare Spending
2.5 Spending on Diagnostics
2.5.1 Important Role of Insurance for Diagnostics

3.1 Players in a Dynamic Market
3.1.1 Diagnostic Test Developer
3.1.2 Instrumentation Supplier
3.1.3 Chemical/Reagent Supplier
3.1.4 Pathology Supplier
3.1.5 Independent Clinical Laboratory
3.1.6 Public National/regional Laboratory
3.1.7 Hospital Laboratory
3.1.8 Physicians Office Lab (POLS)
3.1.9 Audit Body
3.1.10 Certification Body
3.2 Understanding Antimicrobial Resistance
3.2.1 What is Antimicrobial Resistance (AMR)
3.2.2 Bacteria and Other Microbes
3.2.3 The History of Antibiotics
3.2.4 The Role of Animal Husbandry
3.2.5 The Implications of Horizontal Transfer
3.2.6 The Threat of AMR
3.3 The Changing Road to New Antibiotics & Technologies
3.4 The Key Role of Diagnostics in AMR

4.1 The Key Large Market Opportunities in AMR
4.1.1 Streptococcus Pneumoniae (DRSP)
4.1.2 Campylobacter (DRC)
4.1.3 Clostridium Difficile (CD)
4.1.4 Staphylococcus aureus (MRSA)
4.1.5 Neisseria gonorrhoeae (DRNG)
4.1.6 Salmonella (DRNTS)
4.2 Diagnostic Technology Development Opportunities
4.2.1 What’s Wrong with Microbiology
4.2.2 The Features Battleground of Infectious Disease Diagnostics
4.2.3 Multiplex vs. POC/Rapid
4.2.4 The Miracle of Genetics
4.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation
4.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing.
4.2.7 Markers of Resistance.
4.2.8 What Happens to the Microbiology Lab?

5.1 Antibiotic Resistance Recent Developments
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 FDA Clears New bioMérieux Diagnostic System and Panel
5.3 Selux Diagnostics Phenotyping System Gets FDA Approval
5.4 New diagnostics to tackle drug resistant infections
5.5 Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels
5.6 Three companies join forces to tackle antimicrobial resistance (AMR)
5.7 T2 Biosystems Exercises BARDA Option
5.8 OpGen to Ramp up Use of Acuitas AMR Gene Panel
5.9 BD Partners With Pfizer, Wellcome to Study AMR Dx
5.10 Sepsis Test Developers Accelerate Plans
5.11 OpGen Receives FDA Clearance for AMR Panel
5.12 Visby Medical - Rapid Uptake of Handheld PCR Test for STIs
5.13 MicroGenDx, OrthoKey Clinic and OrthoKey Surgery
5.14 BioMérieux Receives CE Mark for Vitek Clinical Microbiology System
5.15 Hologic to Acquire Mobidiag
5.16 Campylobacter strains exchange genes
5.17 Disinfection spreads antimicrobial resistance
5.18 Molzym, Fraunhofer Developing Rapid Sepsis Dx
5.19 Illumina, IDbyDNA Build NGS-Based Respiratory Panel
5.20 Accelerate Diagnostics Expands AMR Testing
5.21 Rapid diagnostics linked to optimal antibiotics
5.22 Visby Medical Wins AMR Diagnostic Competition
5.23 DNAe Technology SARS-CoV-2 Sequences
5.24 Infections with foodborne bacteria becoming harder to treat
5.25 Dust is sharing antibiotic resistance genes

6.1 1928 Diagnostics
6.2 Abacus Diagnostica
6.3 Abbott Laboratories
6.4 Accelerate Diagnostics
6.5 ADT Biotech
6.6 Beckman Coulter Diagnostics
6.7 Becton, Dickinson and Company
6.8 Binx Health
6.9 bioMérieux Diagnostics
6.10 Bio-Rad Laboratories, Inc.
6.11 Cepheid (Danaher)
6.12 Curetis N.V. / Curetis GmbH
6.13 Day Zero Diagnostics.
6.14 Enzo Biochem
6.15 Eurofins Scientific
6.16 Fusion Genomics.
6.17 GeneFluidics
6.18 Genetic Signatures
6.19 Great Basin Corporation
6.20 Hologic
6.21 Hutman Diagnostics
6.22 Inflammatix
6.23 Linear Diagnostics.
6.24 Lumos Diagnostics
6.25 Millipore Sigma
6.26 OpGen
6.27 Ortho Clinical Diagnostics
6.28 Perkin Elmer
6.29 Qiagen
6.30 Roche Molecular Diagnostics
6.31 SeLux Diagnostics
6.32 Sense Biodetection
6.33 Siemens Healthineers
6.34 Sysmex
6.35 Thermo Fisher Scientific Inc.
6.36 Visby Medical

7.1 Global Market Overview by Country.
7.1.1 Table - Global Market by Country
7.1.2 Chart - Global Market by Country
7.2 Global Market by Technology - Overview
7.2.1 Table - Global Market by Pathogen
7.2.2 Chart - Global Market by Pathogen - Base/End Year Comparison
7.2.3 Chart - Global Market by Pathogen - Base Year
7.2.4 Chart - Global Market by Pathogen - End Year
7.2.5 Chart - Global Market by Pathogen - Share by Year
7.2.6 Chart - Global Market by Pathogen - Segment Growth
7.3 Global Market by Technology - Overview
7.3.1 Table - Global Market by Technology
7.3.2 Chart - Global Market by Technology - Base/End Year Comparison
7.3.3 Chart - Global Market by Technology - Base Year
7.3.4 Chart - Global Market by Technology - End Year
7.3.5 Chart - Global Market by Technology - Share by Year
7.3.6 Chart - Global Market by Technology - Segment Growth

8.1 Drug Resistant Streptococcus Pneumoniae - DRSP
8.1.1 Table DRSP - by Country
8.1.2 Chart - DRSP Growth
8.2 Drug Resistant Campylobacter - DRC
8.2.1 Table DRC - by Country
8.2.2 Chart - DRC Growth
8.3 Clostridium Difficile - CD
8.3.1 Table CD - by Country
8.3.2 Chart - CD Growth
8.4 Methicillin Resistant Staphylococcus Aureus - MRSA
8.4.1 Table MRSA - by Country
8.4.2 Chart - MRSA Growth
8.5 Drug Resistant Neisseria Gonorrhoeae - DRNG
8.5.1 Table DRNG - by Country
8.5.2 Chart - DRNG Growth
8.6 Drug Resistant Salmonella - DRNTS
8.6.1 Table DRNTS - by Country
8.6.2 Chart - DRNTS Growth

9.1 Microbiology Culture
9.1.1 Table Culture - by Country
9.1.2 Chart - Culture Growth
9.2 Immunoassay
9.2.1 Table Immunoassay - by Country
9.2.2 Chart - Immunoassay Growth
9.3 PCR
9.3.1 Table PCR - by Country
9.3.2 Chart - PCR Growth
9.4 NGS
9.4.1 Table NGS - by Country
9.4.2 Chart - NGS Growth
9.5 Mass Spectrometry - MS
9.5.1 Table MS - by Country
9.5.2 Chart - MS Growth
9.6 Rapid and Point of Care - Rapid/POC
9.6.1 Table Rapid/POC - by Country
9.6.2 Chart - Rapid/POC Growth

11.1 United States Medicare System: Clinical Laboratory Fees Schedule

Table 1  Market Players by Type
Table 2  Known Human Pathogenic Diseases
Table 3 The Key Market Opportunities
Table 4 - Market Potential DRSP Diagnostic
Table 5 - Market Potential DRC Diagnostic
Table 6 - Market Potential CD Diagnostic
Table 7 - Market Potential CD Diagnostic
Table 8 Market Potential DRNG Diagnostic
Table 9 Market Potential DRNTS Diagnostic
Table 10 - Key AMR Diagnostics Issues
Table 11 - Global Market by Region
Table 12 Global Market by Pathogen
Table 13 Global Market by Technology
Table 14 DRSP by Country
Table 15  DRC by Country
Table 16 CD by Country
Table 17 MRSA by Country
Table 18 DRNG by Country
Table 19 DRNTS by Country
Table 20  Culture by Country
Table 21 Immunoassay by Country
Table 22  PCR by Country
Table 23  NGS by Country
Table 24  MS by Country
Table 25  Rapid/POC by Country
Table 26 Clinical Lab Fee Schedule

Figure 1 Global Healthcare Spending Map
Figure 2 The Lab Test Pie
Figure 3 The Road to Diagnostics
Figure 4 AMR and Antibiotic Introduction
Figure 5 The Death Toll of AMR
Figure 6  Global Market Share Chart
Figure 7 Global Market by Pathogen - Base vs. End Year
Figure 8 Global Market by Pathogen Base Year
Figure 9 Global Market by Pathogen End Year
Figure 10 Pathogen Share by Year
Figure 11 Pathogen Segment Growth
Figure 12 Technology - Base vs. End Year Segment Shift.
Figure 13 Technology Market Base Year
Figure 14 Technology Market End Year
Figure 15 Technology Share by Year
Figure 16 Technology Segment Growth
Figure 17 DRSP Growth
Figure 18 DRC Diagnostics Growth
Figure 19 CD Growth
Figure 20 MRSA Growth
Figure 21 DRNG Growth
Figure 22 DRNTS Growth
Figure 23 Culture Growth
Figure 24 Immunoassay Growth
Figure 25 PCR Growth
Figure 26 NGS Growth
Figure 27 MS Growth
Figure 28 Rapid/POC Growth